Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Ability to understand and sign a written informed consent documen；
At the date of signing ICF, 18 ~70 years old, male or female；
Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
Positive mesothelin expression;
None
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Collaborator